Genome Medical operates as an independent virtual medical practice powered by a digital health technology platform (its Genome Care DeliveryTM platform) to deliver on-demand genetic insights, clinical assessments, test ordering and personalized care plans. The company partners with health systems, providers, health plans, employers, labs and biopharma to expand access to genomic medicine. Genome Medical announced the acquisition of GeneMatters, which will operate as a wholly owned subsidiary focused on expanding genetic services to community health systems and other partners. The company plans to use proceeds from its recent financing to expand its team and further develop configurable technology solutions, physician services, test ordering capabilities and guidelines-based care plans. Headquartered in South San Francisco, Genome Medical positions itself to accelerate adoption of genomic services across health systems, research studies, health plans, employers and diagnostic labs. Genome Medical is a telegenomics technology, services and strategy company that delivers virtual genetic care through a nationwide network of genetic specialists and its Genome Care Delivery technology platform. The company provides expert virtual genetic care for individuals and their families and helps health care providers and patients navigate genetics to understand disease risk, accelerate diagnosis, inform treatment decisions and lower cost of care. Its solutions are utilized by health systems, hospitals, payors, providers and employers, and the company also serves patients directly and accepts self-referrals. Led by CEO and co-founder Lisa Alderson, Genome Medical focuses on applying genomic-based medicine across clinical settings. The company intends to use new funding to accelerate development of its Genome Care Delivery platform for cancer, reproductive health and pharmacogenomics. Since 2016 the company has raised a total of $60M, including the latest round. Genome Medical operates a cloud-based genomic care delivery platform that provides on-demand access to genetic experts for virtual visits, provider-to-provider consults, genetic wellness assessment, and screening for population health management. The company partners with hospitals, health systems, payers, providers, and employers to make genomic medicine accessible to patients nationwide. Led by co-founder and CEO Lisa Alderson, Genome Medical is based in South San Francisco, California. The company plans to scale its team of clinical genomics specialists and accelerate development of its proprietary genomic care delivery platform using the new funding. Financially, Genome Medical has raised a total of $46M since its founding in 2016, including the current Series B. The new capital is intended to expand service delivery and product development across its healthcare and employer customers. Genome Medical operates a telegenomics platform that connects a network of clinical genetics experts with patients and clinicians to provide genetic counseling and physician services. The company delivers genetic counseling in all 50 states and physician services in 30 states, covering nearly three-quarters of the U.S. population. It accepts insurance billing, institutional billing, and direct patient payment. Genome Medical plans to expand all services nationwide in 2018 and to deepen clinical offerings in cancer genetics, cardiovascular genetics, reproductive health and proactive health. The company was co-founded in 2016 and is headquartered in San Francisco. It has raised more than $23 million in financing to date. Genome Medical operates a telehealth platform that connects patients with genetic counselors, geneticists, or contracted specialists for phone or video consultations. The service is designed to increase access and reduce wait times, offering next-day scheduling and working toward same-day appointment capabilities. Consultations currently cost $149 for a video visit, and the company is pursuing insurance coverage. Genome Medical offers both pre-test “proactive health” counseling and post-test consultations that include a detailed clinical action plan. The company has formed partnerships (including Good Start Genetics) and is building out a team of doctors to integrate genetic testing into clinical care. It was founded by CEO Lisa Alderson with Randy Scott and Harvard Medical School geneticist Robert Green and has raised $12 million in funding from institutional investors.

Total raised

$132M

Funding rounds

5

Latest round

Series C

Latest activity

Aug 2021